CIWT yields 500000.00% · ABBV yields 3.06%● Live data
📍 CIWT pulled ahead of the other in Year 1
Combined, CIWT + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of CIWT + ABBV for your $10,000?
China Industrial Waste Management, Inc. provides environmental services and solutions in northeastern China. The company collects, stores, treats, disposes, and recycles industrial solid waste through incineration and/or landfill, physical and/or chemical treatment, material processing, packaging, analysis, and storage. It is also involved in the treatment of municipal sewage, as well as sludge resulting from the processing of sewage that is routed from the sewage treatment facilities located in Dalian and surrounding areas. The company operates a sewage treatment facility and a sludge treatment facility in Dalian, as well as provides environmental pollution remediation services to the Dalian municipal government. In addition, it offers environmental protection, technology consultation, pollution treatment, waste management design processing, waste disposal, waste transportation, and onsite waste management services. The company sells its recycled materials, including cupric sulfate, as well as metals and methane derived from sludge treatment to commodity traders and metallurgical companies. China Industrial Waste Management, Inc. was founded in 1991 and is based in Dalian, China.
Full CIWT Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.